The efficacy and safety of pramipexole augmentation in treatment resistant depression: Results of the PAX-D trial.
There has been interest in the use of dopaminergic agonists in patients with treatment resistant depression (TRD), although they have only been assessed in small-scale, short-term studies. We conducted a substantial RCT examining the effect and safety/tolerability of the dopamine agonist pramipexole in patients with TRD, the PAX-D trial. In this talk I will present the efficacy and safety results from the trial.

This seminar is hosted in person and online, to join online, please use the Zoom details below:

zoom.us/j/93598736019?pwd=tHJ65nmXIrmYTUhi7YRbbdlnyi5Ie6.1
Meeting ID: 935 9873 6019
Passcode: 897963
Date: 4 March 2025, 9:30
Venue: Department of Psychiatry, Headington OX3 7JX
Venue Details: Seminar Room
Speaker: Professor Michael Browning (Department of Psychiatry, University of Oxford)
Organising department: Department of Psychiatry
Organiser: Rania Elgarf (Department of Psychiatry, University of Oxford)
Organiser contact email address: rania.elgarf@psych.ox.ac.uk
Host: Professor Phil Cowen (Professor of Psychopharmacology, University of Oxford )
Part of: Psychiatry Seminar Series
Booking required?: Not required
Audience: Public
Editor: Rania Elgarf